Viking Therapeutics Stock Forecast
NASDAQ: VKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 12:19 PM ET
VKTX analyst consensus
Consensus (20 analysts)
strong_buy
Avg. price target
$94.71+230.58%
- Strong buy 5
- Buy 13
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 20 Wall Street analysts covering Viking Therapeutics (2026-10-07), 18 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $94.71, with a high estimate of $125.00 and a low estimate of $38.00. The average target implies upside of 230.6% from the current price of $28.65.
The spread between the highest and lowest targets is 228.9%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VKTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 5 | 25% |
| Buy | 13 | 65% |
| Hold | 2 | 10% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $38.00 | +32.64% |
| Average target | $94.71 | +230.58% |
| High target | $125.00 | +336.30% |